Trial Profile

A phase 1/2 trial of FCR001 in patients with diffuse cutaneous systemic sclerosis (SSc)

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 09 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FCR 001 (Primary)
Indications Diffuse scleroderma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

06 Oct 2020 According to a Talaris Therapeutics media release, the Series B financing co-led by Surveyor Capital (a Citadel company) and Viking Global Investors will support this study.
10 Jul 2020 New trial record
08 Jul 2020 According to a Talaris Therapeutics media release, this study is planned at the sites across the USA, including Duke University and the University of Michigan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com